Drug Profile
Research programme: lysosomal storage disease therapeutics - Oxyrane
Alternative Names: LSD 2; LSD 3; LSD 4; LSD 5; OXY-2810Latest Information Update: 26 Feb 2023
Price :
$50
*
At a glance
- Originator Oxyrane
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gaucher's disease; Glycogen storage disease type II; Lysosomal storage diseases
Most Recent Events
- 26 Feb 2023 Preclinical development is ongoing for Glycogen-storage-disease-type-II in United Kingdom (Oxyrane website; February 2023)
- 24 Feb 2023 Preclinical development is ongoing for Lysosomal storage diseases in United Kingdom (Oxyrane website; February 2023)
- 24 Feb 2023 Preclinical trials in Gaucher's disease in United Kingdom (Parenteral) (Oxyrane website; February 2023)